News | Vivacelle Bio

Recent News

Vivacelle Bio Enrolls First Patient in Phase 3 Trial of Hypovolemia Due to Septic Shock for Phospholipid Nanoparticle-Based VBI-S

KANSAS CITY, Mo., Sept. 3, 2024 /PRNewswire/ -- Vivacelle Bio , a late-stage biopharma company developing life-saving treatments for...

Surge in Septic Shock Care: Vivacelle’s Innovative Approach

https://www.clinicaltrialvanguard.com/executiveinterviews/surge-in-septic-shock-care-vivacelles-innovative-approach/

Vivacelle Bio Initiates Phase 3 Trial for Lead Asset VBI-S to Treat Patients with Hypovolemia Due to Septic Shock

https://www.prnewswire.com/news-releases/vivacelle-bio-initiates-phase-3-trial-for-lead-asset-vbi-s-to-treat-patients-with-hypovolemia-du...

Vivacelle Bio Given the Business Expansion Award by the Metro Chamber Alliance of Greater Fort Wayne

April 29, 2020 - VIVACELLE BIO GIVEN THE BUSINESS EXPANSION AWARD BY THE METRO CHAMBER ALLIANCE OF GREATER FORT WAYNE

Black Doctor Says He Has Developed Clinical Treatment For COVID-19 Patients That Increases Oxygen Levels

VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients

See Trial Information here: https://clinicaltrials.gov/study/NCT04257136?tab=table

Vivacelle Bio Provides its Sepsis Treatment for COVID-19 Via Compassionate Use

April 22, 2020 Vivacelle Biosciences said it will make its experimental sepsis treatment VBI-S available for compassionate use in...

Vivacelle Bio Announces Compassionate Use for COVID-19 Patients with Its Sepsis Treatment, VBI-S

Most COVID patients die of septic shock. In early studies VBI-S improved blood pressure and oxygenation of septic shock patients when all...

Vivacelle Bio granted IND

February 15, 2019 CHICAGO--(BUSINESS WIRE)--Vivacelle Bio, Inc. today announces that the US. Food and Drug Administration (FDA) has...

A New Organ Protective, Volume Expanding, Perfusion (VBI-1) Fluid Based On Phospholipid Nanoparticles as the Colloid

CEO of Vivacelle Bio at Syracuse College of Law

43North Finals Pitch - Vivacelle Bio